Scholarlink

<p>Repeated semiannual azithromycin mass drug administration (MDA) to children has been shown to reduce all-cause childhood mortality. However, antibiotic resistance is a major public health concern as the program is being implemented in sub-Saharan Africa. In the double-blind, cluster-randomized, placebo-controlled trial (AVENIR) in Niger, we evaluated the impact of azithromycin MDA targeting different age groups on mortality and on the gut and nasopharyngeal microbiome and resistome of children in participating communities. A total of 3,000 communities were randomized in a 1:1:1 allocation to 3 arms: 2 years of semiannual MDA of (1: child–azithromycin) azithromycin to 1–59-month olds, (2: infant–azithromycin) azithromycin to 1–11-month olds and placebo to 12–59-month olds or (3: placebo) placebo to 1–59-month olds. Mortality (co-primary endpoint) and safety data have previously been published. Here we report on resistance (the co-primary endpoint). One hundred fifty communities (50 per arm) were selected for this analysis. A total of 4,382 rectal and 4,402 nasopharyngeal samples were included. The co-primary outcomes included changes in gut and nasopharynx macrolide AMR. The trial met its primary AMR endpoint for the gut but not for the nasopharynx. The gut macrolide AMR burden in fold change between arms was highest in child–azithromycin compared with placebo (1.16, 95% confidence interval (CI): 1.06–1.28; <i>P</i> &lt; 0.01), followed by child–azithromycin compared with infant–azithromycin (1.13, 95% CI: 1.02–1.23; <i>P</i> = 0.01), and infant–azithromycin compared with placebo (1.04×, 95% CI: 0.94–1.15×; <i>P</i> = 0.66). There were no statistically significant differences in macrolide AMR selection fold change in the nasopharynx between arms: 2.14 (95% CI: 0.93–4.99) for child–azithromycin versus placebo, 2.08 (95% CI: 0.93–4.69) for infant–azithromycin versus placebo, and 1.03 (95% CI: 0.46–2.30) for child–azithromycin versus infant–azithromycin. Close monitoring of AMR should be an essential component of MDA for childhood mortality. ClinicalTrials.gov registration: <a href="http://clinicaltrials.gov/ct2/show/NCT04224987">NCT04224987</a></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mass azithromycin distribution and antibiotic resistance in the gut and nasopharynx: a cluster-randomized trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月17日

查看全文
  • Thuy Doan,
  • Daisy Yan,
  • Ahmed M. Arzika,
  • Amza Abdou,
  • Ramatou Maliki,
  • Bawa Aichatou,
  • Ismael Mamane Bello,
  • Diallo Beidi,
  • Nasser Galo,
  • Naser Harouna,
  • Alio M. Karamba,
  • Sani Mahamadou,
  • Moustapha Abarchi,
  • Almou Ibrahim,
  • Lina Zhong,
  • Cindi Chen,
  • YuHeng Liu,
  • Danny Yu,
  • Thomas Abraham,
  • Angela S. Cheng,
  • Brittany Peterson,
  • Catherine E. Oldenburg,
  • Travis C. Porco,
  • Benjamin F. Arnold,
  • Armin Hinterwirth,
  • Elodie Lebas,
  • Kieran S. O’Brien,
  • Thomas M. Lietman

摘要

Repeated semiannual azithromycin mass drug administration (MDA) to children has been shown to reduce all-cause childhood mortality. However, antibiotic resistance is a major public health concern as the program is being implemented in sub-Saharan Africa. In the double-blind, cluster-randomized, placebo-controlled trial (AVENIR) in Niger, we evaluated the impact of azithromycin MDA targeting different age groups on mortality and on the gut and nasopharyngeal microbiome and resistome of children in participating communities. A total of 3,000 communities were randomized in a 1:1:1 allocation to 3 arms: 2 years of semiannual MDA of (1: child–azithromycin) azithromycin to 1–59-month olds, (2: infant–azithromycin) azithromycin to 1–11-month olds and placebo to 12–59-month olds or (3: placebo) placebo to 1–59-month olds. Mortality (co-primary endpoint) and safety data have previously been published. Here we report on resistance (the co-primary endpoint). One hundred fifty communities (50 per arm) were selected for this analysis. A total of 4,382 rectal and 4,402 nasopharyngeal samples were included. The co-primary outcomes included changes in gut and nasopharynx macrolide AMR. The trial met its primary AMR endpoint for the gut but not for the nasopharynx. The gut macrolide AMR burden in fold change between arms was highest in child–azithromycin compared with placebo (1.16, 95% confidence interval (CI): 1.06–1.28; P < 0.01), followed by child–azithromycin compared with infant–azithromycin (1.13, 95% CI: 1.02–1.23; P = 0.01), and infant–azithromycin compared with placebo (1.04×, 95% CI: 0.94–1.15×; P = 0.66). There were no statistically significant differences in macrolide AMR selection fold change in the nasopharynx between arms: 2.14 (95% CI: 0.93–4.99) for child–azithromycin versus placebo, 2.08 (95% CI: 0.93–4.69) for infant–azithromycin versus placebo, and 1.03 (95% CI: 0.46–2.30) for child–azithromycin versus infant–azithromycin. Close monitoring of AMR should be an essential component of MDA for childhood mortality. ClinicalTrials.gov registration: NCT04224987